Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Clin Cancer Res. 2011 Jun 28;17(15):4975–4986. doi: 10.1158/1078-0432.CCR-10-3328

Figure 3. IL-7-mediated protection from tumor-induced phenotypic alterations depends on PI3K and AKT.

Figure 3

(A) and (B) Tumor-exposed T cells were cultured with or without IL-7 and with LY294002 (LY) or AKT inhibitor IV. On day 7, cells were stained with CD27 and CD28 antibodies. One representative of the 3 is shown in (A), data from independent 3 experiments are shown in (B), with each bar representing the mean of triplicate values ±SD. (C) T cells alone or tumor-exposed T cells treated with IL-7 or together with LY294002 or AKT inhibitor IV were cultured for the indicated periods. Cell lysates were resolved with 10% SDS-PAGE and immunoblotted with indicated antibodies. Total AKT was used as a loading control.